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Abstract: A kidney- transplanted Saudi patient presented with a skin rash for 
which he was treated as fungal infection .The patient developed these lesions 
20 years after transplantation. The clinical picture was that of Kaposi’s 
sarcoma which was confirmed by histopathology .The patient developed 
these lesions after he was shifted to prednisolone and mycophenolate mofetil 
after four years of prednisolone, azathioprine and cyclosporine 
immunosuppressive therapy. 
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arcoma is a cancer that develops 
in connective tissues such as 
cartilage, bone, muscle, blood 
vessel or fibrous tissue. In 1872 Moritz Kaposi 
first described “Idiopathisches multiple 
pigmentsarkom der Haut” which has become 
known as Kaposi sarcoma (KS)1.  It was 
postulated that Kaposi sarcoma, especially in 
patients with advanced skin tumors are reactive 
proliferations rather than true malignancies with 
metastatic dissemination2.  
 KS has several types: Classic KS 
which was considered a rare disease that mostly 
affects elderly men of Mediterranean or Jewish 
heritage, African KS (Endemic) including the 
fatal infantile KS, Transplant-Related KS 
(Acquired) and AIDS-Related (Epidemic) 
Kaposi sarcoma3.  
 In the last 20 years most of KS cases 
were associated with HIV infection 
 It was found that KS risk is high in 
immunosuppressed transplant recipients, and 
most cases occurred in the first two years after 
transplantation.  The risk increases steadily with 
recipient age, and in males4. 
KS is 150 – 200 times more likely to 
develop in transplanted patients than in general 
population. There is strong evidence that KS 
develops in recipients with pre-existing 
infection with human herpes virus 8(HHV-8) 3,4.  
According to Tessari etal5  only combined 
immunosuppressive therapy with 
mycophenolate mofetil + cyclosporine + 
prednisolone were independently associated 
with KS.  
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 Case report: 
A 45 –years- old man was seen in post renal 
transplant clinic with multiple skin lesions. 
The lesion were diagnosed initially and 
treated as fungal infection (Tinea corporis). 
The patient had renal transplant 20 years prior 
to this presentation. He was on 
immunosuppressive therapy. Firstly, he was 
on prednisolone, azathioprine and cyclosporin 
for four years, and then shifted to 
prednisolone plus mycophenolate mofetil 
only. He was on regular follow up by the 
renal unit.  
 Clinical evaluation of the patient 
revealed a large violet patch (15x10cm) over 
the surface of the right lower half of the 
abdomen   (see figure 1)  
 
Figure(1) shows a large (15x!0xcm) violet patch on 
the right lower half of the abdomen. 
 
There were also violet multiple nodules seen 
over the upper part left chest over the left 
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Figure(2) shows multiple nodules over the left breast. 
 
 
In addition, there are two violet patches 
(2x3cm each) seen on the lateral side of the 
right upper arm and another patch on the right 
thigh.  
Blood tests revealed normal white blood cells 
count (11000), platelet count (157) but a high 
ESR (45 mm/hr), a low haemoglobin (7.2 
gm/dl), a high blood urea (71mg/dl) and a 
high creatinine (2.0mg/dl) otherwise normal 
chemistry.  
Sputum was negative for AFB  
Serological tests for both HIV and VDRL 
were negative. 
Chest X-ray showed multiple infiltrations 
with patchy opacities bilaterally in the lower 
parts of both lungs suggestive of metastasis. 
















Figure (4) Chest X-ray of the patient showing multiple 
infiltrations with patchy opacities on the lower parts of 
lungs. 
 
Ultra sound of the abdomen showed 
shrunken parental kidney while the 
transplanted kidney was obscured by gases. 
Liver was coarse and in-homogenous echo  
texture with echo-poor area suggestive of 
metastasis while pancreas and spleen were 
normal and no ascitis was seen. CT scan was 
recommended but it was not possible to 
perform before patient’s death. 
Upper gastrointestinal endoscopy showed 
ulcerated nodular lesions with bleeding 
mucosa in the greater curvature and the 
middle body of the stomach. It was not 
possible to take a biopsy from these lesions 
because of the instability of the patient. 
The patient was referred to dermatology 
department where a skin biopsy from the 
lesions revealed a thinned out epidermis. 
Dermis and subcutaneous tissue showed 
spindle shape cells proliferation seen in 
fascicles with separating slit-like vascular 
spaced lined by mildly atypical nuclei. There 
were extravasations of red blood cells and 
haemosidrin pigmentation. The superficial 
part showed ill-defined vascular proliferation, 
newly formed vascular formation and 
inflammatory infiltrates (Figures5, 6, and 7), 
these findings were consistent with the 
diagnosis of Kaposi sarcoma. 
 
  
Fig 5,6 and 7 show the histopathogical findings 
 
Discussion: 
KS is a multifocal vascular tumor that occurs 
most commonly in patients who have 
immunosuppression6. It is the most common 
malignancy encountered in renal transplant 
recipients7. It is seen up to 400 times more 
frequently in transplant patients compared to 
normal population8. 
The highest percentage for post renal 
transplant K.S is reported from Saudi Arabia9. 
KS was found to be the most common 
malignancy encountered in renal transplant 
recipients in Iraq with a prevalence of 2.9% 7. 
Altaee et al7indicated that the average latency 
period between transplantation and 
development of malignancy was 6.5 months 
for KS. However, Italian organ transplant 
recipients have an increased risk (about 100 
times greater) for Kaposi sarcoma compared  
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to general population especially during the 
first two years after transplantation5.  
Post renal transplant KS is related more to the 
immunosuppressive protocol containing 
cyclosporine compared to azathioprine8. It has 
been suggested that cyclosporine is a risk 
factor for the development of KS as it has a 
direct cancer promoting effect by cell-
autonomous mechanisms10.  
On the other hand, regression of KS has been 
reported on replacing cyclosporine by 
mycophenolate mofetil11. 
Hussein etal reported disappearance of KS 
after replacing cyclosporine and azathioprine 
by mycophenolate mofetil12. However, even 
after the cessation of cyclosporine and 
azathioprine and replacing them with 
mycophenolate mofetil in our reported case, 
KS developed. This might supports earlier 
reports13. It is not very clear whether the 
introduction of mycophenolate mofetil 
contributed to the appearance of KS in our 
patient or not. Some reports showed a higher 
(0.8%) incidence for developing KS while on 
mycophenolate mofetil treatment compared 
with only 0.01% in patients not on 
mycophenolate mofetil treatment14. 
As for the average latency period between 
transplantation and development of KS, some 
reports were as low as 6.5 months others gave 
up to 21 months7, 15. However it was found 
that most cases occurred in the first two years 
after transplantation. Surprisingly our patient 




It is concluded that renal transplant patients 
may develop KS even if shifted from 
cyclosporine to mycophenolate mofetil 
therapy. Post renal KS can occur up to twenty 
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